While higher SGLT2i doses yield marginally greater glucose-lowering effects in T2DM, DAPA-HF and other large HF trial programs tested fixed doses, which are suggested in practice
While higher SGLT2i doses yield marginally greater glucose-lowering effects in T2DM, DAPA-HF and other large HF trial programs tested fixed…